With a major patent cliff coming, will JPM play host to some serious deal-making?

Taking stock of the drug industry, from the lab to the medicine chest

January 8, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Alex Hogan/STAT STAT+ | With a major patent cliff coming, will JPM play host to some serious deal-making? Drugmakers stand to lose $400 billion in revenue as patents expire for Keytruda, Eliquis, and other blockbusters. That could spur deals at JPM 2025. By Allison DeAngelis and Adam Feuerstein STAT+ | Leaving FDA, Califf is unapologetic — and warns of staff departures In an interview, the outgoing commissioner of the agency was wary of Trump administration but unapologetic about controversial decisions during his term. By Matthew Herper STAT+ | Galapagos to split itself into two companies as part of turnaround plan The Galapagos branch will prioritize work in cancer cell therapies, while the spin-out arm aims to build a pipeline through transactions. By Andrew Joseph Adobe STAT+ | Denali Therapeutics spinout raises $200M as neuro company resets Tenvie is carrying over a collection of small molecule drugs that Denali had been developing but decided to discontinue work on. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser